Working… Menu
Trial record 40 of 116 for:    Atenolol

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00185094
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : December 23, 2005
Information provided by:
Daiichi Sankyo, Inc.

Brief Summary:
To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.

Condition or disease Intervention/treatment Phase
Hypertension Insulin Resistance Metabolic Syndrome Drug: Olmesartan medoxomil Drug: Losartan potassium Drug: Atenolol Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension
Study Start Date : February 2004
Study Completion Date : July 2005

Primary Outcome Measures :
  1. To compare the treatment effect of olmesartan medoxomil versus that of atenolol on insulin sensitivity

Secondary Outcome Measures :
  1. -To compare the treatment effect of losartan potassium versus atenolol on insulin sensitivity
  2. -To compare the treatment effect of olmesartan medoxomil versus losartan potassium on insulin sensitivity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients between the ages of 18 and 75 years (inclusive)
  • Willingness to undergo insulin clamp procedure twice
  • Overweight or obese (BMI=25-39 kg/m2)
  • Subject must meet one of the following two blood pressure criteria at week-2 and at week-1: Systolic blood pressure 140-179 mmHg and diastolic blood pressure 85-99 mmHg OR Systolic blood pressure < 140 mmHg and diastolic blood pressure 90-99 mmHg
  • If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study

Exclusion Criteria:

  • Systolic blood pressure > 179 mmHg
  • Diastolic blood pressure > 99 mmHg or < 85 mmHg
  • Diagnosis of diabetes mellitus
  • History of myocardial infraction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, unstable angina pectoris or an episode of heart failure requiring hospitalization
  • Previous history of a cerebrovascular accident or a transient ischemic attack
  • History of allergic response to atenolol, losartan potassium, olmesartan medoxomil or any of their components
  • Any serious disorder, including pulmonary, hepatic, renal, gastrointestinal (including clinically significant malabsorption), uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases, that would interfere with the conduct of the study or interpretation of the data
  • Laboratory abnormalities that could compromise subject safety

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00185094

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, California
San Diego, California, United States
United States, Florida
Miami, Florida, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Minnesota
Rochester, Minnesota, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Texas
Dallas, Texas, United States
San Antonio, Texas, United States
Sponsors and Collaborators
Daiichi Sankyo, Inc.

Layout table for additonal information Identifier: NCT00185094     History of Changes
Other Study ID Numbers: 866-440
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: December 23, 2005
Last Verified: September 2005
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Insulin Resistance
Vascular Diseases
Cardiovascular Diseases
Body Weight
Signs and Symptoms
Glucose Metabolism Disorders
Metabolic Diseases
Olmesartan Medoxomil
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents